Ruxolitinib cream for childhood vitiligo

Ruxolitinib cream (Opzelura) already FDA-approved for nonsegmental vitiligo in patients ≥12 based on TRuE-V1/V2 Phase 3s hitting F-VASI75 at week 24. Pediatric extension (6-<12) uses identical endpoint, same mechanism, vehicle-controlled design. Children typically respond as well or better to vitiligo therapy. Main risks are enrollment/operational, not efficacy. High prior probability of success.

Phase 3, a vehicle comparator, and a prespecified clinically meaningful Week 24 F-VASI75 endpoint support interpretable efficacy testing. However, the 6-to-<12 population adds pediatric uncertainty; no prior efficacy, enrollment, or powering data are provided, and ongoing recruitment leaves execution and disclosure risk.

Phase 3, vehicle-controlled design uses a clear, clinically meaningful Week 24 F-VASI75 endpoint. Ruxolitinib has a targeted topical mechanism and the facial endpoint is sensitive to treatment effect. Pediatric 6-<12 enrollment and long recruitment/execution remain meaningful sources of uncertainty.

Phase 3 status and a vehicle-controlled design support a strong prior for efficacy. F-VASI75 at Week 24 is a specific, clinically meaningful facial endpoint. Children aged 6–<12 may add response variability; recruiting status and the 451-day timeline create execution and disclosure risk before readout.

Phase 3 recruiting trial in pediatric nonsegmental vitiligo using established F-VASI75 endpoint at week 24. Sponsor experienced with agent; no red flags in design, powering details absent, long 2027 timeline adds execution/disclosure risk.

Ruxolitinib cream (Opzelura) is already FDA approved for nonsegmental vitiligo in patients 12 and older. This trial simply extends the age down to 6-11 years. Pediatric label expansions for approved topical drugs have very high historical success rates. The primary endpoint, F-VASI75 at Week 24, is identical to the successful pivotal TRuE-V trials, making technical failure highly unlikely.

Ruxolitinib cream has shown ≥75% F‑VASI improvement in adult trials, indicating strong efficacy. The Phase 3 pediatric study uses the same endpoint, but safety and recruitment in 6‑<12‑year‑olds add uncertainty. Prior data and Phase 3 status suggest >50% chance of a positive result, warranting moderate confidence.

Ruxolitinib cream is FDA-approved for adult vitiligo based on TRuE-V1/V2 Phase 3 trials showing F-VASI75 ~30-50% vs ~10% vehicle. Same mechanism (JAK1/2), same validated endpoint (F-VASI75 at Wk24), same sponsor (Incyte). Pediatric extrapolation carries some risk: potentially different PK/response in ages 6-<12, smaller facial surface area may affect scoring, and pediatric recruitment can be slow. Still recruiting with 451 days to completion adds modest operational risk. Overall high probability of replicating adult efficacy signal given consistent design and validated MoA.